Veru Inc. VERU

Company Overview

Veru Inc. is a U.S.-based biopharmaceutical company focused on developing medicines for metabolic diseases, oncology, and inflammatory conditions. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on late-stage drug development targeting areas with significant unmet medical need. Veru’s current business model is centered on advancing proprietary therapeutics through clinical development and, where applicable, pursuing regulatory approvals and commercialization opportunities. Historically, the company also generated revenue through a sexual health and urology business that included products for condom manufacturing and urological device distribution.

The company’s primary value driver in recent years has been its pharmaceutical pipeline, particularly its obesity and metabolic disease programs involving enobosarm, a selective androgen receptor modulator (SARM) being studied in combination with GLP-1 receptor agonist therapies to address muscle preservation during weight loss. Veru has also pursued oncology programs focused on breast cancer and prostate cancer-related therapies. The company traces its origins to The Female Health Company, which historically focused on female condoms and reproductive health products before rebranding as Veru and transitioning toward a broader biopharmaceutical strategy through acquisitions, licensing agreements, and internal drug development initiatives.